Multicenter phase II study of docetaxel/cisplatin/bevacizumab combination therapy in patients with advanced non-squamous non-small cell lung cancer (TORG1016)
Phase 2
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000004368
- Lead Sponsor
- Thoracic Oncology Research Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 47
Inclusion Criteria
Not provided
Exclusion Criteria
1) brain metastasis 2) histroy of hemoptysis 3) serious complication; cardiac disea se, interstitial peumonia, diabetes, active infection 4) massive pleural or pericardial effusion, ascites 5) concomitant malignancy 6) uncontrollable peptic ulcer or GI perforaion within 1 year 7) uncontrollable hypertension 8) anticoagulation therapy 9) inappropriate for this study judged by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method